Andy Laccetti MD, MS
@alaccetti
Followers
468
Following
2K
Media
26
Statuses
388
GU Medical Oncologist at @Perlmutter_CC NYU Langone. Director of Quality. Investigator of novel PCa therapeutics and patient monitoring systems.
New York, NY
Joined December 2012
ADT remodels the tumor microenvironment from immunologically cold to hot. Matthew Dallos, MD @MSKCancerCenter joins @AndreaMiyahira @PCFnews in this discussion of how androgen deprivation therapy reshapes the immune landscape in localized #ProstateCancer. #WatchNow >
0
7
26
This was the date set in the end of year (2024) appropriations bill passed by the prior Congress and signed by President Biden. This new Congress was always going to have to provide for a statutory extension. We knew this in December. I’m confident Congress will act. Our
What is the rationale for this other than making life more difficult for many seniors?
1
3
12
DARO monotherapy in CSPC after BCR: ARAMON lead-in phase results @urotoday @BayerOncMed #GU25 ☑️n=23 ☑️At wk 12: mean % ⬆️ in T from B/L was 53.5% (95%CI, 33.4–76.5) ☑️PSA responses: - <0.2: 65.2% - PSA50: 100% - PSA90: 78.3% ☑️Feminizing TEAEs - 18/23 pts: - Gr 1
0
12
29
Everyone in academic medicine is hopeful the pause at NIH will be temporary. The research funding pause will affect post doctoral researchers, technicians, and academic research efforts across the United States. https://t.co/OWYKGALY4e
msnbc.com
This is a potentially devastating event — not just for the scientific community, but for all Americans.
1
4
10
Synapse: Your Connection to our MSK Authors Meet: Ritesh Kotecha @KotechaMD Research Focus: Medicine; Assistant Attending Sample site impacts RNA biomarkers for renal cell carcinoma #RenalCellCarcinoma #CancerBiomarkers #RNAResearch
https://t.co/jAwTGzhgyQ
0
2
1
The efficacy and resistance-breaking potential of EPI-7386 masofaniten in castration-resistant #ProstateCancer. @alaccetti @MSKCancerCenter joins @zklaassen_md @GACancerCenter discussing the continuous effort to refine hormonal therapy in #PCa management > https://t.co/2XdNrgusyy
0
2
7
Dual action hormone therapy targeting two parts of the androgen receptor simultaneously shows tolerability and early efficacy in phase I trial. @alaccetti @MSKCancerCenter and @DrRanaMcKay @UCSanDiego discuss recent advancements in #mCRPC treatments > https://t.co/hqEpfHQs2b
0
2
5
‼️ This combination IIT for pts w refractory penile cancer supported by @GSKUS is accruing pts @MoffittNews @SpiessPhilippe and soon at @MDAndersonNews @CurtisPettaway1 and @uscnorris please offer this option to your pts and reach out w questions @GTumors
📣New Trial Alert! @JadChahoud shares a study for platinum-resistant penile cancer now open at @MoffittNews and soon to open at @MDAndersonNews and @uscnorris. Hypothesis: PARPi activates cGAS-STING pathway sensitizing cis-resistant PSCC to anti-PD-(L)1 therapy #DAVABroadmoorGU
0
4
18
Masofaniten Plus Enzalutamide Demonstrates Safety and Durable Responses in mCRPC @alaccetti @MSKCancerCenter @myESMO #ESMO23 #pcsm
onclive.com
Masofaniten administered in combination with enzalutamide (Xtandi) was tolerable, pharmacokinetically active, and led to a decrease in prostate-specific antigen levels at the recommended phase 2 dose...
0
1
3
We are pleased to announce the PCCTC-managed study of EPI-7386 in combination with enzalutamide in subjects with metastatic prostate cancer has entered phase 2. For more information visit: https://t.co/KlW3EYyvoO
0
2
2
ADT interruption in patients responding exceptionally to AR-pathway inhibitor in #mHSPC: A-DREAM. @AtishChoudhury and @CaPsurvivorship @DanaFarber discuss the right balance of treatment duration for patients with metastatic prostate cancer > https://t.co/adsrTa9GY1
0
1
4
Andrew Laccetti, MD, MS, at @MSKCancerCenter underscores “to date, androgen receptor (AR) pathway inhibitors either competitively antagonize the receptor via the ligand-binding domain or block androgen synthesis.” https://t.co/gKDDYBRDua
@alaccetti #ESMO23
0
4
7
Phase 1/2 Trial: Oral EPI-7386 + Enza vs Enza Alone in mCRPC: Ph 1 Results #ESMO23 @urotoday @alaccetti 📍To date, n=18 📍Safety: consistent w/ 2nd-gen antiandrogens 📍PK results: Enza minimally impacted by EPI-7386 --> full dose Enza (160 mg) in cohort 4 📍Evaluable data:
0
11
11
⭐️Unprecedented amount of PRACTICE CHANGING studies in GU oncology @myESMO this weekend. Looking forward to seeing these presentations from @BradMcG04 @DrChoueiri @neerajaiims @tompowles1 @apolo_andrea @sartor_oliver @Silke_Gillessen @OncoAlert Dates and times 👇
1
30
94
We are hiring a Genitourinary Medical Oncologist to provide outstanding patient-centered care at our Monmouth Regional site in NJ. We are looking for either a clinical investigator or a clinician for this role. Join a great team! See ad for details. https://t.co/IZ2yfDoUnb
1
10
34
In this editorial, Susan F. Slovin, MD, PhD, reviews the recent trial by @DrSpratticus et al. and discusses the prospects and limitations of applying an AI-based predictive model to guide treatment for prostate cancer. #MedicalAI #PCSM #UroSoMe @MSKCancerCenter @KimmelCancerCtr
1
5
11
Been working on a mini-comic about cancer cachexia. Cancer cachexia can be one of the most emotionally-charged symptoms we work with in clinic, for patients AND families. #palliativecare #supponc #hapc #wip #graphicmedicine
3
43
163